Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma
about
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Current Views on Anthracycline Cardiotoxicity in Childhood Cancer SurvivorsBNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculographyExpert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography.Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.Cardiac toxicity of high-dose chemotherapy.Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity.Anthracycline cardiotoxicity.Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patientsCardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy.Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast CancerAnthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicityNew and emerging biomarkers of heart failure.Chemotherapy-induced cardiomyopathy.Biological drugs: classic adverse effects and new clinical evidences.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.Anthracycline-Induced Cardiomyopathy in Adults.Alternative Biomarkers for Combined Biology.Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation?Decitabine induced transient cardiomyopathy: a case reportNatriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.Concomitant impairment of left ventricular systolic and diastolic function during doxorubicin therapy: a prospective radionuclide ventriculographic and echocardiographic study.Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure.Plasma natriuretic peptides levels and echocardiographic findings in late subclinical anthracycline toxicity.
P2860
Q27027354-0376A67F-9536-4465-BA8E-E7D36480FD64Q28083073-62A83DDD-FBC1-43BC-96F7-14AF54D269D7Q28538548-E15CB306-2289-4488-A288-5917C9F53249Q30401812-2484680D-88A0-4AE0-B2F0-32068BDB3E99Q30500830-CB14F0DC-6583-4DD2-B1FA-773E85757A60Q33896047-97CF0891-5708-4856-917B-BB55C32AD9A2Q34659375-0F166BEC-2CE7-4DBD-A813-30F4BE8B4E3DQ35949084-998D387F-7C99-4F9E-BC57-52BEDD303925Q36150546-14E6160C-8A82-469A-8A7A-BDB83290F9E2Q36624983-83926719-05F3-4039-BFF1-FE9BFA712E6AQ36644505-B28CD479-3A4C-44E9-AEC8-3A0705CEA49CQ36676062-E441605A-7093-4C28-BC41-469DE4105822Q36788268-BD902270-B2A3-49F5-AF22-F650372AEDE0Q37059896-ED300145-EB55-4428-800A-C23AC6093709Q37230118-0230710A-3ECB-4FCA-98F7-6280352CF947Q37514230-76F04A10-0BA5-47A5-B84A-A7886084B625Q37867085-634AB87F-F57E-42C1-8849-4551176B56D3Q38015746-925852DE-3C47-46E6-8674-81B8D6BC0BF7Q38166071-3FC0B2DF-E048-483E-A1C2-622331462DB7Q38542462-75CE8F07-DA57-4DAF-A2C9-11DA929DE1CBQ38747992-2DEA2DD5-6E0C-4765-A845-F77A2D0F0BA3Q41030597-DE3A40C3-95F1-48EC-9219-7A9623B68F0CQ42430693-5FB31BF1-0992-4861-A189-4A1637D782A9Q43910722-42760517-2E58-4E9A-8AF5-3458FEE0CCFCQ44397250-5E8566E3-2A87-4A20-9707-AD7AF1208FE7Q44918082-89A334BE-D37C-474A-B89F-D557AF90A687Q46772677-CCD2312B-9A99-4ABC-AA24-39F90F9C4635Q48225190-37AF095E-DFD5-4632-B2E1-4451638D1660Q48809762-04A2AF34-6976-413B-A915-CC35A792B6CF
P2860
Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Natriuretic peptides as marker ...... ent for non-Hodgkin's lymphoma
@ast
Natriuretic peptides as marker ...... ent for non-Hodgkin's lymphoma
@en
Natriuretic peptides as marker ...... ent for non-Hodgkin's lymphoma
@nl
type
label
Natriuretic peptides as marker ...... ent for non-Hodgkin's lymphoma
@ast
Natriuretic peptides as marker ...... ent for non-Hodgkin's lymphoma
@en
Natriuretic peptides as marker ...... ent for non-Hodgkin's lymphoma
@nl
prefLabel
Natriuretic peptides as marker ...... ent for non-Hodgkin's lymphoma
@ast
Natriuretic peptides as marker ...... ent for non-Hodgkin's lymphoma
@en
Natriuretic peptides as marker ...... ent for non-Hodgkin's lymphoma
@nl
P2093
P3181
P1476
Natriuretic peptides as marker ...... ent for non-Hodgkin's lymphoma
@en
P2093
E Jantunen
E Vanninen
J Hartikainen
O Vuolteenaho
T Nousiainen
P2860
P304
P3181
P356
10.1111/J.1600-0609.1999.TB01734.X
P407
P577
1999-02-01T00:00:00Z